HOME >> MEDICINE >> NEWS
JCI table of contents: May 4, 2006

AUTHOR CONTACT:
Paul J. Bryce
Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA.
Phone: (312) 503-0077; Fax: (312) 503-0078; E-mail: p-bryce@northwestern.edu.

View the PDF of this article at: https://www.the-jci.org/article.php?id=26150

BONE BIOLOGY

Peptide inhibitor may prevent bone loss in osteoporosis

Two molecules known as RANK and TNFR promote the differentiation of osteoclasts cells that are responsible for the breakdown of bone. This process occurs in healthy individuals as part of the constant renewal of the bone that makes up our skeleton, and it occurs at an increased rate in individuals with diseases such as osteoporosis, rheumatoid arthritis, and periodontal disease. A site on TNFR that is critical for the binding of activating molecules is also conserved, in part, on RANK. In a study appearing online on May 4 in advance of print publication in the June issue of the Journal of Clinical Investigation, Roland Baron and colleagues from Yale University School of Medicine show that mimicking a critical loop of TNFR and RANK with a small cyclic peptide allows the inhibition of RANK ligandinduced bone breakdown and resorption in mouse models of osteoporosis. The authors used molecular modeling to demonstrate the exact region where the peptide binds and interferes with RANK signaling. These findings pave the way for the development of new strategies for designing peptide as well as nonpeptide inhibitors of RANK ligandinduced osteoclast-mediated bone loss, which is a key pathway in the mechanisms at work in many bone and joint diseases.

TITLE: A TNF receptor loop peptide mimic blocks RANK ligandinduced signaling, bone resorption, and bone loss

AUTHOR CONTACT:
Roland Baron
Yale University School of Medicine, New Haven, Connecticut, USA.
'"/>

Contact: Brooke Grindlinger
press_releases@the-jci.org
212-342-9006
Journal of Clinical Investigation
4-May-2006


Page: 1 2 3 4

Related medicine news :

1. International symposium on fruit, vegetables headed for Houston
2. Stevens Roundtable: Health, Technology & Society, July 11
3. FDA approves ZYFLO CR extended-release tablets for chronic treatment of asthma
4. Once-fatal metabolic disorders treatable, says Stanford/Packard researcher
5. Clinical review -- A psychological approach to the management of irritable bowel syndrome
6. JCI table of contents -- May 17, 2007
7. JCI table of contents: May 10, 2007
8. New treatments needed for irritable bowel syndrome
9. JCI table of contents: May 1, 2007
10. Americans still not eating enough fruits and vegetables, according to 2 recent studies
11. Slow-release morphine reduces level of intractable cough

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:3/29/2017)... ... March 29, 2017 , ... ... oral braces. "The rubber bands used in conjunction with my braces always rubbed ... to design a way to prevent this problem." The O.B.S. was the result ...
(Date:3/29/2017)... ... 2017 , ... Immunotherapy has emerged as one of the most promising options ... be the next revolution in our fight against this complex disease. One of the ... checkpoint inhibitors such as PD-1 and PD-L1 inhibitors. , While a few single analyte ...
(Date:3/29/2017)... ... March 29, 2017 , ... Physicians’ Education Resource® (PER®), ... medical education conference for clinicians who manage some of the most difficult-to-treat forms ... , The program will be led by co- chairs Dr. John Marshall, chief ...
(Date:3/29/2017)... (PRWEB) , ... March 29, 2017 , ... VisualSP has ... sustainably. Until recently, the only option for on-premises installation of its Help System for ... required to install the system into the entire tenant. , The company recently ...
(Date:3/28/2017)... ... March 28, 2017 , ... For many women, getting birth control isn’t as easy as it ... either don’t have access to a health care facility or a pharmacy within 60 minutes ... the United States or for many who are faced with health or personal issues that ...
Breaking Medicine News(10 mins):
(Date:3/28/2017)... March 28, 2017  Medeon Biodesign, Inc., a ... is pleased to announce that the Company led ... Panther Orthopedics, Inc., a San Jose, ... solutions for orthopedic extremity applications.  ... rapidly, primarily due to procedure volume growth, lifestyle ...
(Date:3/28/2017)...  "US Cancer Generics Market Outlook 2022" report ... trend analysis related to the emergence and integration ... in US. The report analyzes various clinical and ... generics drugs in recent years. The introduction of ... dollars for various stake holders involved US cancer ...
(Date:3/28/2017)... 2017  Orexigen Therapeutics, Inc. (Nasdaq: OREX ... fourth quarter and year ended December 31, 2016. ... progress for Orexigen, beginning with the re-acquisition of the ... March, the team at Orexigen demonstrated remarkable focus, executing ... and strengthened our Company while rewarding us full control ...
Breaking Medicine Technology:
Cached News: